239 related articles for article (PubMed ID: 20957124)
1. Treating Lennox-Gastaut syndrome in epileptic pediatric patients with third-generation rufinamide.
Gresham J; Eiland LS; Chung AM
Neuropsychiatr Dis Treat; 2010 Oct; 6():639-45. PubMed ID: 20957124
[TBL] [Abstract][Full Text] [Related]
2. Adjunctive Rufinamide in Children with Lennox-Gastaut Syndrome: A Literature Review.
Balagura G; Riva A; Marchese F; Verrotti A; Striano P
Neuropsychiatr Dis Treat; 2020; 16():369-379. PubMed ID: 32103957
[TBL] [Abstract][Full Text] [Related]
3. Role of rufinamide in the management of Lennox-Gastaut syndrome (childhood epileptic encephalopathy).
Kluger G; Bauer B
Neuropsychiatr Dis Treat; 2007 Feb; 3(1):3-11. PubMed ID: 19300535
[TBL] [Abstract][Full Text] [Related]
4. Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide.
Stafstrom CE
Neuropsychiatr Dis Treat; 2009; 5():547-51. PubMed ID: 19898669
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of rufinamide as adjunctive therapy in patients with Lennox Gastaut syndrome: A systematic review and Meta-analysis.
Sharawat IK; Panda PK; Panda P; Dawman L
Seizure; 2021 Oct; 91():296-307. PubMed ID: 34273668
[TBL] [Abstract][Full Text] [Related]
6. Rufinamide: a pharmacoeconomic profile of its use as adjunctive therapy in Lennox-Gastaut syndrome.
McCormack PL
Pharmacoeconomics; 2012 Mar; 30(3):247-56. PubMed ID: 22332960
[TBL] [Abstract][Full Text] [Related]
7. Current role of rufinamide in the treatment of childhood epilepsy: literature review and treatment guidelines.
Coppola G; Besag F; Cusmai R; Dulac O; Kluger G; Moavero R; Nabbout R; Nikanorova M; Pisani F; Verrotti A; von Stülpnagel C; Curatolo P
Eur J Paediatr Neurol; 2014 Nov; 18(6):685-90. PubMed ID: 24929673
[TBL] [Abstract][Full Text] [Related]
8. Real-world data on rufinamide treatment in patients with Lennox-Gastaut syndrome: Results from a European noninterventional registry study.
Nikanorova M; Brandt C; Auvin S; McMurray R
Epilepsy Behav; 2017 Nov; 76():63-70. PubMed ID: 28927712
[TBL] [Abstract][Full Text] [Related]
9. Rufinamide: a new antiepileptic medication for the treatment of seizures associated with lennox-gastaut syndrome.
Wisniewski CS
Ann Pharmacother; 2010 Apr; 44(4):658-67. PubMed ID: 20233912
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of rufinamide in children and adults with Lennox-Gastaut syndrome: A post hoc analysis from Study 022.
Arzimanoglou A; Pringsheim M; Kluger GJ; Genton P; Perdomo C; Malhotra M
Epilepsy Behav; 2021 Sep; 124():108275. PubMed ID: 34509883
[TBL] [Abstract][Full Text] [Related]
11. Dosing considerations for rufinamide in patients with Lennox-Gastaut syndrome: Phase III trial results and real-world clinical data.
Kothare S; Kluger G; Sachdeo R; Williams B; Olhaye O; Perdomo C; Bibbiani F
Seizure; 2017 Apr; 47():25-33. PubMed ID: 28284045
[TBL] [Abstract][Full Text] [Related]
12. Rufinamide efficacy and safety in children aged 1-4 years with Lennox-Gastaut syndrome.
Kim SH; Kang HC; Lee JS; Kim HD
Brain Dev; 2018 Nov; 40(10):897-903. PubMed ID: 30166208
[TBL] [Abstract][Full Text] [Related]
13. Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan.
Ohtsuka Y; Yoshinaga H; Shirasaka Y; Takayama R; Takano H; Iyoda K
Epilepsy Res; 2014 Nov; 108(9):1627-36. PubMed ID: 25219353
[TBL] [Abstract][Full Text] [Related]
14. The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK.
Benedict A; Verdian L; Maclaine G
Pharmacoeconomics; 2010; 28(3):185-99. PubMed ID: 20151724
[TBL] [Abstract][Full Text] [Related]
15. Proposed anti-seizure medication combinations with rufinamide in the treatment of Lennox-Gastaut syndrome: Narrative review and expert opinion.
Sankar R; Chez M; Pina-Garza JE; Dixon-Salazar T; Flamini JR; Hyslop A; McGoldrick P; Millichap JJ; Resnick T; Rho JM; Wolf S
Seizure; 2023 Aug; 110():42-57. PubMed ID: 37321047
[TBL] [Abstract][Full Text] [Related]
16. Rufinamide for the treatment of Lennox-Gastaut syndrome: evidence from clinical trials and clinical practice.
Striano P; McMurray R; Santamarina E; Falip M
Epileptic Disord; 2018 Feb; 20(1):13-29. PubMed ID: 29313492
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Adults with Lennox-Gastaut Syndrome: Further Analysis of Efficacy and Safety/Tolerability of Rufinamide.
McMurray R; Striano P
Neurol Ther; 2016 Jun; 5(1):35-43. PubMed ID: 26861566
[TBL] [Abstract][Full Text] [Related]
18. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome.
Glauser T; Kluger G; Sachdeo R; Krauss G; Perdomo C; Arroyo S
Neurology; 2008 May; 70(21):1950-8. PubMed ID: 18401024
[TBL] [Abstract][Full Text] [Related]
19. Update on rufinamide in childhood epilepsy.
Coppola G
Neuropsychiatr Dis Treat; 2011; 7():399-407. PubMed ID: 21792306
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and seizure outcome in Japanese patients with Lennox-Gastaut syndrome receiving adjunctive rufinamide therapy: An open-label study following a randomized clinical trial.
Ohtsuka Y; Yoshinaga H; Shirasaka Y; Takayama R; Takano H; Iyoda K
Epilepsy Res; 2016 Mar; 121():1-7. PubMed ID: 26827266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
